This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (39)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Glaucoma  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Arch Ophthalmol. 2003;121:729-730.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Intravitreal injections of triamcinolone acetonide have increasingly been used for treatment of various intraocular neovascular, proliferative, or edematous diseases, such as diffuse diabetic macular edema, proliferative diabetic retinopathy, proliferative vitreoretinopathy, chronic uveitis, and persistent pseudophakic cystoid macular edema.^1-6 In view of the widening spectrum of therapeutic indications of intravitreal triamcinolone acetonide, we report the clinical course of a patient who repeatedly received intravitreal injections of triamcinolone acetonide 14 months apart, who showed intravitreal triamcinolone acetonide crystals still present 9 months after the second injection, and who developed secondary open-angle glaucoma uncontrollable by topical antiglaucomatous medication.

Report of a Case

A 79-year-old woman sought treatment for progressive exudative age-related macular degeneration with subfoveal occult neovascularization in her left eye. Snellen chart visual acuity decreased from 0.80 to 0.50 OS with the accompanying complaint of marked metamorphopsia. Intraocular pressure measured 16 mm Hg, and the appearance of the optic nerve head was normal. The right eye . . . [Full Text of this Article]

Comment
Corresponding author: Jost B.Jonas, MD, Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany (e-mail: jost.jonas@ma.augen.uni-heidelberg.de).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections
Tammewar et al.
Br. J. Ophthalmol. 2008;92:810-813.
ABSTRACT | FULL TEXT  

Intravitreal anti-inflammatory treatment for uveitis
Sugita
Br. J. Ophthalmol. 2007;91:135-136.
FULL TEXT  

Intraocular pressure alterations following intravitreal triamcinolone acetonide
Rhee et al.
Br. J. Ophthalmol. 2006;90:999-1003.
ABSTRACT | FULL TEXT  

Argon Laser Trabeculoplasty for Intractable Glaucoma Following Intravitreal Triamcinolone
Viola et al.
Arch Ophthalmol 2006;124:133-134.
FULL TEXT  

Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jonas et al.
Arch Ophthalmol 2005;123:1338-1343.
ABSTRACT | FULL TEXT  

Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study
Jonas et al.
Br. J. Ophthalmol. 2005;89:321-326.
ABSTRACT | FULL TEXT  

Intravitreal Triamcinolone Acetonide for Macular Edema Associated With Diabetic Retinopathy and Venous Occlusive Disease: It's Time for Clinical Trials
Flynn and Scott
Arch Ophthalmol 2005;123:258-259.
FULL TEXT